# Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension

> **NCT01756430** · PHASE3 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 238 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Carvedilol SR 32mg, QD
- **DRUG:** Carvedilol SR 64mg, QD
- **DRUG:** Carvedilol IR 25mg, QD
- **DRUG:** Carvedilol IR 25mg, BID

## Key facts

- **NCT ID:** NCT01756430
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 238 (ACTUAL)
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01756430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01756430, "Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01756430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*